Sector News

Sorin Group Signs Merger Agreement with Cyberonics

March 25, 2015
Life sciences
(BUSINESS WIRE) – Sorin S.p.A., a global medical device company and a leader in the treatment of cardiovascular diseases, is pleased to announce that Sorin and Cyberonics Inc. in furtherance of the merger plan unanimously approved by their boards of directors, as disclosed in the joint statement of 26 February 2015, have signed today the relevant definitive merger agreement. The transaction remains subject to certain conditions including, without limitation: approval by both Sorin and Cyberonics’ shareholders, the receipt of required antitrust and regulatory clearances, and other customary closing conditions.
 
The combination of Sorin and Cyberonics will create a new premier global medical technology company. This merger is expected to drive significant value for shareholders by leveraging combined strengths, capturing new opportunities and creating new solutions to benefit patients and healthcare professionals alike and is particularly exciting for employees, who will be able to share technical expertise and innovate faster.
 
Sorin will provide further updates as the process progresses and relevant documents are available at www.sorin.com.
 
Source: Sorin Group

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach